Prothena | PRTA - Net Income


Prothena reported $-36.54M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Exelixis USD 193.58M 8.73M Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Prothena USD -36.54M 89.23M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025